patient subgroup...
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
antiviral and associated therapy - versus control - for COVID 19 all comers
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 death D28 0.73 [0.52, 1.03]< 1 0% 1 study (2/-) 96.4 % NA not evaluable crucial - deaths 0.55 [0.37, 0.84]< 1 0% 2 studies (5/-) 99.7 % some concern not evaluable moderate crucial - deaths (time to event analysis only) 0.55 [0.36, 0.84]< 1 0% 1 study (1/-) 99.7 % NA not evaluable crucial - clinical deterioration 2.07 [0.06, 66.79]< 1 0% 1 study (1/-) 34.3 % NA not evaluable important - clinical improvement 1.29 [1.12, 1.49]> 1 0% 2 studies (2/-) 100.0 % some concern not evaluable moderate important - clinical improvement (14-day) 1.25 [0.21, 7.62]> 1 0% 1 study (1/-) 59.5 % NA not evaluable important - clinical improvement (28-day) 1.35 [1.03, 1.76]> 1 0% 1 study (1/-) 98.7 % NA not evaluable important - clinical improvement (time to event analysis only) 1.29 [1.12, 1.49]> 1 0% 1 study (1/-) 100.0 % NA not evaluable important - hospitalization 0.29 [0.08, 1.07]< 1 0% 1 study (1/-) 96.8 % NA not evaluable important - mechanical ventilation 2.07 [0.06, 66.79]< 1 0% 1 study (1/-) 34.3 % NA not evaluable important - mechanical ventilation (time to event analysis only) 0.43 [0.16, 1.14]< 1 0% 1 study (-/1) 95.5 % NA not evaluable important - viral clearance 0.18 [0.01, 4.75]> 1 0% 1 study (2/-) 15.7 % NA not evaluable important - viral clearance (time to event analysis only) 0.82 [0.36, 1.87]> 1 0% 1 study (1/-) 31.9 % NA not evaluable important - viral clearance by day 14 0.18 [0.01, 4.75]> 1 0% 1 study (1/-) 15.7 % NA not evaluable important - viral clearance by day 7 0.58 [0.14, 2.48]> 1 0% 1 study (1/-) 23.3 % NA not evaluable important - ICU admission 5.43 [0.21, 139.89]< 1 0% 1 study (1/-) 15.7 % NA not evaluable non important - safety endpoints 00 serious adverse events 0.72 [0.54, 0.96]< 1 0% 1 study (1/-) 98.8 % NA not evaluable important - adverse events 1.92 [0.31, 12.05]< 1 0% 1 study (1/-) 24.3 % NA not evaluable non important - deep vein thrombosis 0.64 [0.23, 1.81]< 1 0% 1 study (1/-) 80.0 % NA not evaluable non important - elevated liver enzymes 0.67 [0.38, 1.18]< 1 0% 1 study (1/-) 91.8 % NA not evaluable non important - hyperbilirubinemia 0.84 [0.30, 2.34]< 1 0% 1 study (1/-) 62.9 % NA not evaluable non important - pulmonary embolism 0.96 [0.19, 4.80]< 1 0% 1 study (1/-) 51.7 % NA not evaluable non important - renal impairment 1.02 [0.64, 1.61]< 1 0% 1 study (1/-) 47.2 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.